Edition:
United Kingdom

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

332.15USD
16 Feb 2018
Change (% chg)

$-1.03 (-0.31%)
Prev Close
$333.18
Open
$334.00
Day's High
$341.00
Day's Low
$329.00
Volume
387,449
Avg. Vol
325,481
52-wk High
$543.50
52-wk Low
$313.86

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $50,356.19
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

Regeneron CEO says fears over Eylea 'greatly exaggerated'

Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company's fourth-quarter results.

08 Feb 2018

UPDATE 3-Regeneron CEO says fears over Eylea "greatly exaggerated"

* Shares rise as much as 5 percent (Adds CEO, president comments; updates share price)

08 Feb 2018

BRIEF-Regeneron Reports Q4 Adj. Earnings Per Share $5.23

* REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

08 Feb 2018

Regeneron posts 31 percent drop in quarterly profit

Feb 8 Regeneron Pharmaceuticals Inc's quarterly profit fell about 31 percent on Thursday, due to a charge of $381 million related to changes in U.S. tax laws.

08 Feb 2018

Regeneron forms consortium to accelerate gene sequencing project

Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

08 Jan 2018

UPDATE 1-Regeneron forms consortium to accelerate gene sequencing project

Jan 8 Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

08 Jan 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

08 Jan 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

08 Jan 2018

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS, Jan 8 France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

08 Jan 2018

BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy

* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY

08 Jan 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.68 -1.12
Pfizer Inc. (PFE.N) $36.26 +0.55
Bayer AG (BAYGn.DE) €97.78 -0.76
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.30 -0.20
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Amgen, Inc. (AMGN.OQ) $183.55 -0.05
Roche Holding Ltd. (ROG.S) CHF223.15 -2.35
Roche Holding Ltd. (RO.S) CHF226.00 -4.20
Eli Lilly and Co (LLY.N) $78.97 +0.95

Earnings vs. Estimates